Literature DB >> 17024282

Polycationic calix[8]arenes able to recognize and neutralize heparin.

Tommaso Mecca1, Grazia M L Consoli, Corrada Geraci, Rita La Spina, Francesca Cunsolo.   

Abstract

A mutual induced fit mechanism is responsible for the exceptional complexation performances exhibited by calix[8]arene polycations towards heparin. The recognition process was studied in comparison with two other heparin antagonists: protamine and polylysine. The arrangement of multiple functional groups on the flexible macrocyclic scaffold of calix[8]arene, with respect to the conformationally rigid protamine and low ordered polylysine, allowed a mutual adaptability between calixarene polycations and heparin, significantly enhancing the recognition performances. Fluorescence, NMR titration, and activated partial thromboplastin time (aPTT) experiments confirmed that these calixarene derivatives have a very high specificity and affinity towards heparin neutralization as in aqueous solution as in blood. Analogous results were obtained with low molecular weight heparin (LMWH) whose effect protamine is unable to completely reverse.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024282     DOI: 10.1039/b608887b

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  14 in total

1.  Dendrigraft of Poly-l-lysine as a Promising Candidate To Reverse Heparin-based Anticoagulants in Clinical Settings.

Authors:  Benjamin Ourri; Jean-Patrick Francoia; Gerald Monard; Jean-Christophe Gris; Julien Leclaire; Laurent Vial
Journal:  ACS Med Chem Lett       Date:  2019-05-08       Impact factor: 4.345

2.  Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.

Authors:  Andrew J Gale; Darlene J Elias; Patricia M Averell; Paul S Teirstein; Mitchell Buck; Steven D Brown; Zinaida Polonskaya; Andrew K Udit; M G Finn
Journal:  Thromb Res       Date:  2011-04-14       Impact factor: 3.944

3.  A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents.

Authors:  Charles E Mahan
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

Review 4.  Targeting heparin and heparan sulfate protein interactions.

Authors:  Ryan J Weiss; Jeffrey D Esko; Yitzhak Tor
Journal:  Org Biomol Chem       Date:  2017-06-27       Impact factor: 3.876

5.  Surfen, a small molecule antagonist of heparan sulfate.

Authors:  Manuela Schuksz; Mark M Fuster; Jillian R Brown; Brett E Crawford; David P Ditto; Roger Lawrence; Charles A Glass; Lianchun Wang; Yitzhak Tor; Jeffrey D Esko
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-25       Impact factor: 11.205

6.  Heparin antagonism by polyvalent display of cationic motifs on virus-like particles.

Authors:  Andrew K Udit; Chris Everett; Andrew J Gale; Jennifer Reiber Kyle; Mihri Ozkan; M G Finn
Journal:  Chembiochem       Date:  2009-02-13       Impact factor: 3.164

Review 7.  Supramolecular hosts as in vivo sequestration agents for pharmaceuticals and toxins.

Authors:  Chun-Lin Deng; Steven L Murkli; Lyle D Isaacs
Journal:  Chem Soc Rev       Date:  2020-10-12       Impact factor: 54.564

8.  Chitosan-capped gold nanoparticles for selective and colorimetric sensing of heparin.

Authors:  Zhanguang Chen; Zhen Wang; Xi Chen; Haixiong Xu; Jinbin Liu
Journal:  J Nanopart Res       Date:  2013-08-25       Impact factor: 2.253

9.  Small molecule antagonists of cell-surface heparan sulfate and heparin-protein interactions.

Authors:  Ryan J Weiss; Philip L S M Gordts; Dzung Le; Ding Xu; Jeffrey D Esko; Yitzhak Tor
Journal:  Chem Sci       Date:  2015-07-29       Impact factor: 9.825

10.  De novo design of self-assembling foldamers that inhibit heparin-protein interactions.

Authors:  Geronda L Montalvo; Yao Zhang; Trevor M Young; Michael J Costanzo; Katie B Freeman; Jun Wang; Dylan J Clements; Emma Magavern; Robert W Kavash; Richard W Scott; Dahui Liu; William F Degrado
Journal:  ACS Chem Biol       Date:  2014-02-11       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.